What the FDA labels say about taking them together
Aliskiren and lisinopril
Lisinopril's FDA label of January 2, 2025 names aliskiren in its contraindications section; aliskiren's label does not name lisinopril itself but warns about its class (ACE inhibitors). The lisinopril label: “… enzyme inhibitor hereditary or idiopathic angioedema Do not co-administer aliskiren with ZESTRIL in patients with diabetes.”
Check it at the source: the aliskiren FDA label on DailyMed (effective March 7, 2024, LXO US Inc.); the lisinopril FDA label on DailyMed (effective January 2, 2025, Upsher-Smith Laboratories, LLC).
What does the aliskiren label say about lisinopril?
Aliskiren's label does not name lisinopril itself; it warns about its class (ACE inhibitors):
Aliskiren label, warnings and precautionsIn general, avoid combined use of Tekturna with ACE inhibitors or ARBs, particularly in patients with creatinine clearance (CrCl) less than 60 mL/min [see Contraindications ( 4 ), Drug Interactions ( 7 ) and Clinical Studies ( 14.3 )].
Aliskiren label, drug interactionsIn general, avoid combined use of aliskiren with ACE inhibitors or ARBs, particularly in patients with CrCl less than 60 mL/min.
Source: FDA drug label (Tekturna), NDA021985 (Lxo Ireland), as published by LXO US Inc., effective March 7, 2024 (SPL set 3dd61fa5-1620-4ebf-bbdb-ede29b92fce2), via openFDA; the full label on DailyMed
What does the lisinopril label say about aliskiren?
Lisinopril label, contraindicationsZestril is contraindicated in patients with: a history of angioedema or hypersensitivity related to previous treatment with an angiotensin converting enzyme inhibitor hereditary or idiopathic angioedema Do not co-administer aliskiren with ZESTRIL in patients with diabetes [see Drug Interactions (7.4) ].
Lisinopril label, drug interactionsBlockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy.
Source: FDA drug label (Qbrelis, NDA208401), Azurity Pharmaceuticals, Inc., effective December 16, 2025 (SPL set 9f6e4e57-a489-4b36-b093-b93865d3717c), via openFDA
Source: FDA drug label (Zestril), NDA019777 (Twi Pharms), as published by Upsher-Smith Laboratories, LLC, effective January 2, 2025 (SPL set 838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Aliskiren | Lisinopril | |
|---|---|---|
| Labeled for | High blood pressure | High blood pressure, Heart attack and coronary artery disease, Heart failure |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $3.94 per tablet 150 mg tablet | $0.0254 per tablet 20 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once